Publicacións nas que colabora con J. García González (10)

2024

  1. A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma

    Frontiers in Immunology, Vol. 15

2023

  1. Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial

    ESMO Open, Vol. 8, Núm. 4

2021

  1. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415

2020

  1. PD-(L)1 inhibitors in combination with chemotherapy as first-line treatment for non-small-cell lung cancer: A pairwise meta-analysis

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-13

2019

  1. Evaluation of the lung immune prognostic index in advanced nonsmall cell lung cancer patients under nivolumab monotherapy

    Translational Lung Cancer Research, Vol. 8, Núm. 6, pp. 1078-1085

2017

  1. Anti-PD-1/PD-L1-induced psoriasis from an oncological perspective

    Journal of the European Academy of Dermatology and Venereology

  2. Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome

    APMIS

  3. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature

    Lung Cancer, Vol. 108, pp. 217-221

  4. Re: Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912–4

    European Urology

2016

  1. Long-term response to nivolumab and acute renal failure in a patient with metastatic papillary renal cell carcinoma and a PD-L1 tumor expression increased with sunitinib therapy: A case report

    Frontiers in Oncology, Vol. 6, Núm. NOV